Related Experiment Video
Updated: Jun 2, 2026
09:38
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Epidermal growth factor receptor targeted therapies for solid tumours.
M Van den Eynde1, J F Baurain, F Mazzeo
1Department of Medical Oncology, Centre du Cancer, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium.
Acta Clinica Belgica
|April 14, 2011
Summary
This review covers anti-epidermal growth factor receptor (EGFR) therapies, including monoclonal antibodies and small-molecule inhibitors, used for various epithelial cancers. It discusses their clinical efficacy, optimal use controversies, and resistance mechanisms.
Area of Science:
- Oncology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) pathways are often activated in human epithelial cancers.
- Current treatments include anti-EGFR monoclonal antibodies (e.g., cetuximab) and small-molecule tyrosine kinase inhibitors (e.g., erlotinib).
Purpose of the Study:
- To summarize clinical evidence for anti-EGFR treatment efficacy in various cancers.
- To discuss current clinical controversies regarding the optimal use of anti-EGFR therapies.
- To briefly review mechanisms of resistance to anti-EGFR treatments.
Main Methods:
- Review of clinical evidence for anti-EGFR therapies.
- Discussion of clinical controversies and resistance mechanisms.
Main Results:
- Anti-EGFR therapies are approved for metastatic non-small-cell lung cancer, colorectal cancer, head and neck squamous-cell carcinoma, and pancreatic cancer.
- Clinical evidence supports the anticancer activity of these treatments.
Conclusions:
- Anti-EGFR therapies represent a significant advancement in treating various epithelial cancers.
- Optimal clinical use and resistance mechanisms remain important areas for ongoing research and discussion.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...